

January 17, 2026

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039	Listing Compliance National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238
Stock Code: 543213	Stock Code: ROSSARI

Dear Sir/Madam,

Sub.: Outcome of Board Meeting held on Saturday, January 17, 2026

Ref.: Compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With regards to the captioned matter and in compliance with the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulation, 2015 ("Listing Regulations"), as amended, this is to inform you that at the meeting of the Board of Directors of the Company which commenced at 12:30 P.M. and concluded at 01:30 P.M. today i.e. Saturday, January 17, 2026, the Board of Directors of the Company have inter alia approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025 are enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to "Limited Review" and the same are enclosed herewith.

2. In-principle approval for setting-up of greenfield manufacturing facilities by Rossari International Limited Company, wholly owned subsidiary of the Company

Furtherance, to our intimation dated November 30, 2024, December 24, 2024 and October 15, 2025, the Board of Directors of Rossari Biotech Limited have accorded in-principle approval to Rossari International Limited Company, a wholly owned subsidiary, for setting up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA) ("Project").



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

The Project will support the strategic growth of the Company by improving supply capabilities, accelerating speed-to-market and strengthening the Company's position as a major player in manufacturing of specialty chemicals. The Project progress will be subject to customary evaluations and necessary regulatory/statutory approvals and is intended to be funded by way of equity, debt, internal accruals, or a combination of these financing means.

The Company shall make further disclosures as required pursuant to Regulation 30 of the Listing Regulations read with SEBI's Master Circular dated November 11, 2024, as and when there are any material developments.

3. Allotment of Equity Shares under the Rossari Employee Option Plan - 2019

With reference to the in-principle approval received from BSE Limited Letter Ref. No. DCS/FL/MJ/ESOP-IP/1257/2021-22 dated May 25, 2021 and National Stock Exchange of India Limited Letter Ref. No. NSE/LIST/26888 dated May 28, 2021 for issue and allotment of 1500000 Equity Shares of Rs. 2/- each to be issued under Rossari Employee Stock Option Plan - 2019 ("ESOP 2019"), the Board of Directors of the Company approved the allotment of 2000 Equity Shares of Rs. 2/- each fully paid to the grantee on exercise of the options granted pursuant to ESOP 2019.

The said Equity shares shall rank pari passu, in all respects with the existing equity shares of the Company. Consequent, to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company stands increased to Rs. 11,07,66,732 consisting of 55383366 Equity Shares of Rs. 2/- each.

Details required under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure - I**.

4. Sale of office premises located at Kanjurmarg Premises

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, sale of office premises situated at Kanjurmarg, Mumbai. As no business operations are conducted from the premises proposed to be sold, the sale will not have any impact on the Company's business operations. Further, the sale of the said Kanjurmarg premises does not constitute the sale of an undertaking of the Company within the meaning of Section 180(1)(a) of the Companies Act, 2013.

The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 are enclosed as **Annexure - II**.

5. Closure of Rossari Bangladesh Limited, a Wholly Owned Subsidiary of the Company

The Board of Directors of the Company in their meeting held today, i.e. on January 17, 2026, have approved the closure of Rossari Bangladesh Limited, a wholly owned subsidiary of the company, subject to the approval of relevant regulatory authority.

The proposed closure shall not have any impact on the operations of the Company.



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 shall be disclosed on receipt of approval/order.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

Annexure - I

Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sr. No.	Particular	Disclosure - Rossari Employee Stock Option Plan - 2019
1.	Company name and address of Registered Office	Rossari Biotech Limited CIN: L24100MH2009PLC194818 Registered Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079.
2.	Name of the recognised Stock Exchanges on which the Company's shares are listed	1. BSE Limited (BSE) 2. National Stock Exchange of India Limited (NSE)
3.	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with recognised Stock Exchange	Filing date of statement is as follows: 1. BSE Limited: May 20, 2021 2. National Stock Exchange of India Limited: May 25, 2021
4.	Filing No., if any	BSE: 129899 NSE: 26888
5.	Title of the Scheme pursuant to which shares are issued, if any	Rossari Employee Stock Option Plan – 2019
6.	Kind of security to be listed	Equity Shares
7.	Par Value of the shares	Rs. 2/-
8.	Date of Issue of shares	January 17, 2026
9.	Number of shares issued	2,000 Shares
10.	Share Certificate No., if applicable	Not applicable
11.	Distinctive Number of the shares, if applicable	55381367 to 55383366 (both inclusive)
12.	ISIN of the shares if issued in Demat	INE02A801020
13.	Exercise price per share	Rs. 425/-
14.	Premium per share	Rs. 423/-
15.	Total Issued shares after this issue	55383366 Shares
16.	Total Issued share capital after this issue	Rs. 11,07,66,732
17.	Details of any lock-in on the shares	Not Applicable
18.	Date of expiry of lock-in	Not Applicable
19.	Whether shares identical in all respects to existing shares, if not, when will they become identical?	All equity shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if applicable	Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

Annexure - II

The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Sr. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Not applicable
2.	Date on which the agreement for sale has been entered into	The Board has approved the said transaction today i.e. January 17, 2026. Transaction is expected to be completed by March 31, 2026.
3.	The expected date of completion of sale/disposal	Transaction is expected to be completed by March 31, 2026.
4.	Consideration received from such sale/disposal	Consideration of Rs. 25 Crores (plus transfer charges wherever applicable).
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Bhagwati Grand Celebration LLP ("Buyer"). Buyer does not belong to the promoter/ promoter group/group companies.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Buyer is not a related party and hence, it will not fall under related party transaction.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Sale of KanjurMarg premises is not part of a Scheme of Arrangement. Further, the sale of the KanjurMarg premises does not attract the terms of regulation 37A of the Listing Regulations, as it does not constitute an undertaking or substantially the whole of the undertaking for the Company under section 180 (1)(a) of the Companies Act, 2013.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621



Walker Chandiok & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **31 December 2025** and the consolidated year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. We did not review the interim financial results of five subsidiaries included in the Statement, whose financial results reflect total revenues of ₹ 3,630.05 million and ₹ 11,066.19 million, total net profit after tax of ₹ 68.18 million and ₹ 284.88 million, total comprehensive income of ₹ 66.74 million and ₹ 279.97 million, for the quarter and nine-months period ended on 31 December 2025, respectively as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 4.37 million and ₹ 13.42 million and total comprehensive income of ₹ 4.33 million and ₹ 13.39 million, for the quarter and nine-months period ended on 31 December 2025, respectively, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Further, of these subsidiaries and associate, 1 subsidiary is located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their country and which have been reviewed by other auditors under generally accepted auditing standards applicable in their country. The Holding Company's management has converted the financial results of such subsidiary from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of this subsidiary is based on the review report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of five subsidiaries, which has not been reviewed by their auditors, whose interim financial information reflects total revenues of ₹ 10.59 million and ₹ 10.59 million, total net loss after tax of ₹ 6.81 million and ₹ 25.30 million, total comprehensive loss of ₹ 6.41 million and ₹ 23.72 million, for the quarter and nine-months period ended on 31 December 2025, respectively as considered in the Statement. The Statement also includes the Group's share of net profit/(loss) after tax of ₹ (0.35) million and ₹ 0.47 million, and total comprehensive income/(loss) of ₹ (0.35) million and ₹ 0.47 million for the quarter and nine-months period ended on 31 December 2025 respectively, in respect of a joint venture, based on its interim financial information, which have not been reviewed by its auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the aforesaid subsidiaries and joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

For Walker Chandiock & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Bharat Shetty
Partner
Membership No. 106815

UDIN: 26106815XMWVNA4421

Place: Mumbai
Date: 17 January 2026

Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1**List of entities included in the Statement**

Sr. No.	Particulars
Subsidiaries	
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited
6	Rossari Global DMCC
7	Rossari International Company Limited
8	Rossari (Singapore) PTE. Ltd. (Incorporated on 18 December 2025)
Step down subsidiaries	
1	Rossari Biotech Trading FZE
2	Unistar Thai Co. Ltd
Joint Venture	
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
Associate	
1	Romakk Chemicals Private Limited



ROSSARI BIOTECH LIMITED
(AN ISO9001:2005 & 14001:2015 Certified Company)




Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

Rs. in million

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2025	30th September, 2025	31st December, 2024	31st December, 2025	31st December, 2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	5,816.80	5,861.07	5,127.31	17,115.03	15,007.32	20,802.94
Other Income	5.09	16.04	5.51	33.13	22.18	40.09
Total Income	5,821.89	5,877.11	5,132.82	17,148.16	15,029.50	20,843.03
II EXPENSES						
Cost of materials consumed	4,175.99	4,072.12	3,214.75	11,592.10	9,298.73	12,996.44
Purchase of stock-in-trade	109.73	293.88	459.94	693.18	1,308.84	1,647.68
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(277.71)	(357.45)	(174.22)	(555.24)	(291.08)	(311.15)
Employee benefits expense	402.56	377.99	356.94	1,155.20	968.41	1,323.30
Finance costs	76.65	60.91	49.44	194.84	123.09	178.11
Depreciation and amortisation expenses	196.14	182.33	183.20	555.96	488.54	670.73
Other expenses	717.50	755.29	622.28	2,143.27	1,766.51	2,495.85
Total Expenses	5,400.86	5,385.07	4,712.33	15,779.31	13,663.04	19,000.96
III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]	421.03	492.04	420.49	1,368.85	1,366.46	1,842.07
IV Share of profit of joint venture and associate	3.98	4.68	3.32	13.87	8.33	9.78
V Profit before exceptional items and tax [III+IV]	425.01	496.72	423.81	1,382.72	1,374.79	1,851.85
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax [V-VI]	425.01	496.72	423.81	1,382.72	1,374.79	1,851.85
VIII Tax Expense						
Current tax charge	132.08	160.51	144.24	453.64	446.52	590.71
Deferred tax (credit)	(34.81)	(32.55)	(37.45)	(103.38)	(91.07)	(102.64)
Total Tax Expense	97.27	127.96	106.79	350.26	355.45	488.07
IX Profit after tax [VII-VIII]	327.74	368.76	317.02	1,032.46	1,019.34	1,363.78
X Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	(2.87)	(3.41)	1.24	(9.38)	1.31	(12.67)
ii Income tax relating to items that will not be reclassified to profit or loss	0.72	0.86	(0.31)	2.36	(0.33)	3.18
B Items that will be reclassified subsequently to profit or loss						
i Exchange difference on translation of foreign operations	0.94	(0.09)	-	2.11	-	(0.76)
ii Income tax relating to items that will be reclassified to profit or loss	(0.53)	-	-	(0.53)	-	-
Total other comprehensive income/(loss)	(1.74)	(2.64)	0.93	(5.44)	0.98	(10.25)
XI Total comprehensive income (IX + X)	326.00	366.12	317.95	1,027.02	1,020.32	1,353.53
Profit for the period/year attributable to						
Owners of the Company	327.74	368.76	317.02	1,032.46	1,019.34	1,363.78
Non Controlling Interest	-	-	-	-	-	-
	327.74	368.76	317.02	1,032.46	1,019.34	1,363.78
Other Comprehensive Income/(Loss) attributable to						
Owners of the Company	(1.74)	(2.64)	0.93	(5.44)	0.98	(10.25)
Non Controlling Interest	-	-	-	-	-	-
	(1.74)	(2.64)	0.93	(5.44)	0.98	(10.25)
Total Comprehensive Income attributable to						
Owners of the Company	326.00	366.12	317.95	1,027.02	1,020.32	1,353.53
Non Controlling Interest	-	-	-	-	-	-
	326.00	366.12	317.95	1,027.02	1,020.32	1,353.53
Paid up equity share capital (Face value of Rs 2.00 per share)	110.76	110.73	110.71	110.76	110.71	110.73
Other equity						
Earnings per equity share (in Rs.)						
Basic	5.92*	6.66*	5.73*	18.65*	18.44*	24.66
Diluted	5.93*	6.65*	5.72*	18.63*	18.41*	24.63

*Not annualized



K.S

Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 17th January, 2026.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The consolidated financial results include the financial results of four foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited and Rossari (Singapore) Pte Ltd (incorporated on 18th December 2025), two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd. (100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).
4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.
5. During the quarter ended 31st December, 2025, the Holding Company has allotted 14,400 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from 21st November, 2025.

The Group has estimated the revised gratuity liability as at 31st December 2025 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expense in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified.

7. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

For ROSSARI BIOTECH LIMITED




SUNIL CHARI
Managing Director
DIN:00149083

Place : Mumbai
Date : 17th January, 2026



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **31 December 2025** and year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Bharat Shetty
Partner
Membership No. 106815
UDIN: 26106815SRUGWW8412

Place: Mumbai
Date: 17 January 2026

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

Rs. In million

Particulars	Quarter ended			Nine months ended		Year Ended 31st March, 2025
	31st December, 2025	30th September, 2025	31st December, 2024	31st December, 2025	31st December, 2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I INCOME						
Revenue from operations	4,506.58	4,195.12	3,682.78	12,359.28	10,049.75	14,316.28
Other Income	11.41	13.97	10.06	42.80	33.46	57.42
Total Income	4,517.99	4,209.09	3,692.84	12,402.08	10,083.21	14,373.70
II EXPENSES						
Cost of materials consumed	2,749.25	2,508.67	2,098.05	7,375.35	5,524.45	8,111.17
Purchase of stock-in-trade	585.45	717.91	577.39	1,804.20	1,911.79	2,530.00
Changes in inventory of finished goods, work-in-progress and stock-in-trade	25.49	(142.09)	(13.08)	(23.20)	(123.65)	(170.42)
Employee benefit expenses	187.31	173.13	163.63	517.10	442.49	600.11
Finance costs	39.53	24.93	22.78	95.39	65.09	95.84
Depreciation and amortisation expenses	74.69	73.43	74.26	219.62	200.27	276.90
Other expenses	455.27	433.39	357.19	1,238.46	954.32	1,383.07
Total Expenses	4,116.99	3,789.37	3,280.22	11,226.92	8,974.76	12,826.67
III Profit before exceptional items and tax [I-II]	401.00	419.72	412.62	1,175.16	1,108.45	1,547.03
IV Exceptional items	-	-	-	-	-	-
V Profit before tax [III-IV]	401.00	419.72	412.62	1,175.16	1,108.45	1,547.03
VI Tax Expense						
Current tax charge	105.20	112.35	114.74	313.97	298.35	421.86
Deferred tax charge/(credit)	(10.46)	(5.12)	(8.43)	(19.89)	(13.68)	(22.25)
Total Tax Expense	94.74	107.23	106.31	294.08	284.67	399.61
VII Profit after tax [V-VI]	306.26	312.49	306.31	881.08	823.78	1,147.42
VIII Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	(0.94)	(0.93)	(0.04)	(2.81)	(0.12)	(3.75)
ii Income tax relating to items that will not be reclassified to profit or loss	0.23	0.23	0.01	0.70	0.03	0.94
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	(0.71)	(0.70)	(0.03)	(2.11)	(0.09)	(2.81)
IX Total comprehensive income (VII + VIII)	305.55	311.79	306.28	878.97	823.69	1,144.61
Paid up equity share capital (Face value of Rs 2 per share)	110.76	110.73	110.71	110.76	110.71	110.73
Other equity						10,661.01
X Earnings per equity share (in Rs.)						
Basic	5.53*	5.64*	5.53*	15.91*	14.90*	20.75
Diluted	5.53*	5.64*	5.53*	15.90*	14.88*	20.72

*Not annualized



20/12/25



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 17th January, 2026.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 31st December, 2025, the Company has allotted 14,400 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
5. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from 21st November, 2025.

The Company has estimated the revised gratuity liability as at 31st December 2025 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expense in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified.

6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

For ROSSARI BIOTECH LIMITED


SUNIL CHARI
Managing Director
DIN:00149083



Place : Mumbai

Date : 17 January, 2026

